

UNCLASSIFIED

AD NUMBER
ADB263437
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Oct 99. Other requests shall be referred to US Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 15 May 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-98-1-8209

TITLE: Role of Cyclin D1 and cdk Inhibitors in Breast Cancer
Pathogenesis

PRINCIPAL INVESTIGATOR: Paola Castagnino, Ph.D.
R. K. Assoian, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

REPORT DATE: October 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Oct. 99). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick,
Maryland 21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010216 062

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND


Award Number: DAMD17-98-1-8209

Organization: University of Pennsylvania

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.



01/09/01

REPORT DOCUMENTATION PAGE*Form Approved*
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1999	3. REPORT TYPE AND DATES COVERED Annual Summary (30-Sep-98 - 29-Sep-99)	
4. TITLE AND SUBTITLE Role of Cyclin D1 and cdk Inhibitors in Breast Cancer Pathogenesis			5. FUNDING NUMBERS DAMD17-98-1-8209	
6. AUTHOR(S) Paola Castagnino, Ph.D. R. K. Assoian, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, Pennsylvania 19104-3246 E-MAIL: castagnino@pharm.med.upenn.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Oct. 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Extensive molecular, biochemical, cell biological, and cytogenetic studies of breast cancer cell lines and breast cancer biopsies have indicated that overexpression of cyclin D1 plays an important role in breast tumor oncogenesis. The connections between cyclin D and tumorigenesis are strengthened by compelling evidence that D-type cyclins are fundamental to cell cycle regulation of the tumor suppressor protein, Rb. However, overexpression of cyclin D1 fails to induce anchorage-independent cell proliferation and also fails to reproducibly stimulate growth in epithelial cell lines. Furthermore, analysis of breast cancer biopsies indicate that cyclin D1 is overexpressed to the same degree in both the early and late stages of breast cancer. Therefore, cyclin D1 overexpression alone may not be a good indicator of breast cancer. Preliminary data from our laboratory indicates that cyclin D1 overexpression results in upregulation of the cyclin-dependent kinase inhibitor p21 in NIH3T3. We also show in MEFs that LY294002, a PI3K inhibitor, is able to reduce cyclin D1 expression level and to block entry in S phase without affecting the level of the cdk inhibitors, p21 and p27. Therefore we want to study the mechanism underlying these events using a Tet-regulated cell model by modulating the expression of cyclin D1.				
14. SUBJECT TERMS Breast Cancer, cyclin D1, p21,				15. NUMBER OF PAGES 12
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

PC Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Pablo Costafra
PI - Signature Date

Table of Contents

Front Page

Standard form 298

Foreword

Introduction

Body of work

Appendix

p. 5

pp. 6. _____

pp. 10 _____

Introduction

Overexpression of cyclin D1 is a frequent event in breast tumorigenesis. However, increases in cyclin D1 are not sufficient to confer full malignant phenotype to mammary epithelial cells, suggesting that cyclin D1 overexpression cooperates with other genetic lesions to promote tumorigenesis. We have generated a cyclin D1 inducible system to examine effects of controlled cyclin D1 expression on p21 protein expression in monolayer and suspension culture. Ectopic elevation of cyclin D1 protein in NIH-3T3 fibroblasts results in an increase in p21 protein levels. Therefore the aim of this proposal is to investigate the mechanism by which changes in the level of expression of cyclin D1 can account for a deregulation in cell cycle progression. We also show that LY294002, a PI3K inhibitor, partially inhibits cyclin D1 expression and blocks S phase entry. We will use our cyclin D1-inducible cell model to determine if the inhibition of S phase entry is solely because of the reduction of cyclin D1 expression.

Body of work

The induction of cyclin D1 and the phosphorylation of pRb require both growth factor and cell adhesion to the extracellular matrix (ECM). To manipulate the expression of cyclin D1 in both monolayer and suspension, we generated NIH-3T3 cells overexpressing cyclin D1 under a tetracycline-regulated promoter. In this mammalian expression system the presence of tetracycline in regular growth media prevents the binding of the transactivator molecule to the Tet-promoter, while removal of tetracycline allows transcription of the gene of interest under the Tet-promoter. Two independent plasmids, one expressing the transactivator molecule and the other cyclin D1, are required to form the Tetracycline-Off mammalian expression system. The cyclin D1 construct used in the transfection of NIH-3T3 cell lines was engineered as follows: a 1 kb Eco RV/Sma I fragment, containing the mouse cyclin D1 cDNA, was subcloned into the Xba I site of the Tet-operator vector in the sense orientation and named Tet-D1. This construct contains the full-length cyclin D1 cDNA and the 5' UTR but lacks most of the 3' UTR. NIH-3T3 cells were stably transfected using Lipofectamine (GIBCO) with prcTA and Tet-D1 plasmids carrying resistance to geneticin and hygromycin, respectively. Stable transfectants were selected in the presence of hygromycin (0.3mg/ml) and geneticin (G418, 0.5mg/ml). Tetracycline (Tet) was added to these cultures at a final concentration of 2 µg/ml to avoid the ectopic expression of cyclin D1 cDNA during the drug selection.

Twelve independent resistant clones were isolated and maintained in 5% CS-DMEM in the presence of hygromycin, geneticin and tetracycline. The selected clones were then screened for the level of expression of cyclin D1 and p21^{cip1} by Western blot analysis. Briefly, cells were grown to confluence in monolayer in the presence of tetracycline and subsequently serum-starved for 36-48 hours in the absence of tetracycline. Starved cells were trypsinized and reseeded in monolayer or suspension in the presence or absence of tetracycline for different times corresponding to transit through G1 phase. Cells were washed in PBS, scraped from the dishes and collected by centrifugation. Cell pellets were lysed and equal amounts of protein were analyzed on a 10% SDS-polyacrylamide gel. Western blot analysis showed that the induction of cyclin D1 led to increased expression of p21^{cip1} and that this effect occurred whether or not cells were cultured in suspension (Sp) or monolayer (Mn) (Figure 1). However, the effect was most pronounced in suspended cells (Sp), presumably because p21 is downregulated by integrin signals in adherent cells (Bottazzi et al., 1999).




Figure 1. Forced expression of cyclin D1 induces p21cip1. Quiescent cells were replated in monolayer (Mn) and suspension (Sp) and stimulated with 5% FCS in the presence and absence of tetracycline. Western blot analysis was performed with cell lysates prepared at the indicated times after serum stimulation.

An analogous strategy was used to transfect mouse embryo fibroblasts (MEFs) with the same Tet-D1 plasmid described above. Stable transfectants were selected in 10% FCS-DMEM in the presence of hygromycin (0.25mg/ml), geneticin (G418 1mg/ml) and Tet at 2 µg/ml. Eighteen independent clones were isolated and maintained in the medium described above. Analysis of cyclin D1 expression by western blotting identified three clones that overexpressed cyclin D1 in a Tet-repressible manner. These were designated YDM14, YDM15 and YDM18.

Control MEFs and MEFs stably expressing tet-regulated cyclin D1 were then G₀ synchronized by a 48 hr serum-starvation. Cells were then trypsinized, resuspended in 5% FCS-DMEM and replated in monolayer (Mn), or in suspension (Sp) in the presence or absence of tetracycline for 18 hours. Cells were collected, lysed and the amount of cyclin D1 and p21 were determined by Western Blot analysis (Figure 2). The results indicated that the three clones differed in the basal level of cyclin D1 expression observed when the cells were cultured in the presence of tetracycline. Additionally, clones M14 and M18 do not show the usual adhesion requirement for the expression of endogenous cyclin D1 while clone M15 does. Importantly, all three clones showed strong induction of cyclin D1 upon removal of tetracycline. p21 expression, as expected from data previously generated in our laboratory (Zhu et al., 1996, Bottazzi et al., 1999) was upregulated by culturing the cells in the absence of a substratum in all three clones. However, p21 expression was not altered by the induction of cyclin D1, and the lack of a cyclin D1 effect was seen in both adherent and non-adherent cells from all three clones (Figure 2). Thus, analysis in MEFs did not show the same cyclin D-p21 effect observed in NIH-3T3 cells.




Figure 2. Overexpression of cyclin D1 in MEFs does not alter the expression of p21^{cip1}. This experiment was performed similarly to the procedure outlined in Figure legend 1.

Given these results, the proposed follow-up experiment involving tet-regulated expression of cyclin D1 in MEFs from p21- and p27-null mice are no longer justified (aim 1 in the original application). We are considering the possibility that p21 is not being induced because the MEFs are acquiring p53 mutations as a consequence of the time they have been kept in culture. We plan to use the NIH-3T3 cell system to determine if the induction of p21 is due to changes in abundance of its mRNA. This result would support the idea that p53 mutations might be preventing us from seeing the cyclin D1 effect in long-term MEF culture.

Recent reports show that, besides being a potent inhibitor of cyclin E-cdk2, p21 acts as a positive regulator of cell cycle progression by promoting the assembly of cyclin D and cdk4 (LaBaer et al., 1997). Cyclin D-cdk4 also seems to be responsible for the sequestration of p21 and p27, and these effects lead to a complete activation of cyclin E-cdk2 and completion of G1 phase (Sherr and Roberts, 1995). On the basis of these new observations, our initial hypothesis for a strictly inhibitory role of p21 (in response to cyclin D upregulation) is no longer appropriate. Although we still intend to study cyclin D1, we will be placing increased emphasis on understanding how its expression is regulated. In particular, we have generated new data indicating that cyclin D1 protein expression is inhibited in growth factor-stimulated MEFs treated with LY294002, a phosphoinositide-3 kinase (PI-3K) specific inhibitor (Figure 3). Although we do not detect any effects of LY294002 on the expression of either cdk inhibitors, p21 or p27, the inhibition of PI-3 kinase completely blocked S phase entry as monitored by the induction of cyclin A (Figure 3). To determine if the inhibitory effect of PI-3 kinase on S phase entry results solely from its inhibitory effect on the expression of cyclin D1, we will use our Tet-Off cell models in which we can modulate the level of expression of cyclin D1 and ask if forced expression of cyclin D1 is sufficient to overcome the growth inhibitory effect of LY294002 in NIH3T3 cells and MEFs.




Figure 3. Effects of the PI3K inhibitor (LY) in growth factor-stimulated MEFs. In A, G₀-synchronized MEFs were stimulated with purified growth factors for the indicated times with or without LY294002 (25μM). Cell extracts were analyzed by immunoblotting for the levels of cyclinD1, p21 and p27. In B, the expression of cyclin A in the same lysates was analyzed by immunoblotting, cdk4 was used as a loading control.

Appendix

- Generation of stable transfected NIH3T3 with the full-length cDNA of cyclin D1 under a tetracycline suppressible system. Induction of cyclin D1 by removal of tetracycline from the media resulted in upregulation of p21.
- Transfection of mouse embryo fibroblasts (MEFs) with a tetracycline repressible cyclin D1 cDNA and characterization of different clones for the expression level of cyclin D1.
- Analysis of MEFs transfectants for p21 expression following induction of cyclin D1 in monolayer and suspension culture.
- Effects of LY294002, a PI3K inhibitor, in MEFs on the levels of expression of cdk inhibitors and cyclin D1 and cyclin A.

Reportable outcomes:

a) manuscripts: none

b) abstracts/presentations: Castagnino, P., Oluwatosin, Y.E., and Assoian, R.K.
“Overexpression of Cyclin D1 upregulates the cdk inhibitor p21^{cip1}”
Presented at the Era of Hope Meeting, 2000

b) patents and licenses applied for: none

d) degrees obtained: none

e) development of cell lines: We produced two stable fibroblastic cell lines expressing tetracycline suppressible cyclin D1. The full-length cyclin D1 was stably expressed in NIH-3T3 cells and the coding domain of cyclin D1 was stably expressed in mouse embryo fibroblasts.

f) funding applied for: none

g) employment opportunities applied for: Dr. Oluwatosin received an offer of employment from Astra Arcus USA, Inc and accepted that offer.

Abstract

“Overexpression of Cyclin D1 upregulates the cdk inhibitor p21^{cip1},”
Presented at the Era of Hope Meeting, 2000

Extensive molecular, biochemical, cell biological, and cytogenetic studies of breast cancer cell lines and breast cancer biopsies have indicated that overexpression of cyclin D1 plays an important role in breast tumor oncogenesis. The connections between cyclin D and tumorigenesis are strengthened by compelling evidence that D-type cyclins are fundamental to cell cycle regulation of the tumor suppressor protein, Rb. However, overexpression of cyclin D1 fails to induce anchorage-independent cell proliferation and also fails to reproducibly stimulate growth in epithelial cell lines. Furthermore, analysis of breast cancer biopsies indicate that cyclin D1 is overexpressed to the same degree in both the early and late stages of breast cancer. Therefore, cyclin D1 overexpression alone may not be a good indicator of breast cancer. Preliminary data from our laboratory indicates that cyclin D1 overexpression results in upregulation of the cyclin-dependent kinase inhibitor p21. We propose that the compensatory increase in p21 expression negates the expected effects of cyclin D1 overexpression on cell proliferation and anchorage-independent growth and the induction of a full malignant phenotype requires both the overexpression of cyclin D1 and the loss of the cell's ability to upregulate the expression of cdk inhibitors in response to a cyclin D1 challenge.



REPLY TO
ATTENTION OF

DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

MCMR-RMI-S (70-1y)

15 May 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB266022	ADB265793
ADB260153	ADB281613
ADB272842	ADB284934
ADB283918	ADB263442
ADB282576	ADB284977
ADB282300	ADB263437
ADB285053	ADB265310
ADB262444	ADB281573
ADB282296	ADB250216
ADB258969	ADB258699
ADB269117	ADB274387
ADB283887	ADB285530
ADB263560	
ADB262487	
ADB277417	
ADB285857	
ADB270847	
ADB283780	
ADB262079	
ADB279651	
ADB253401	
ADB264625	
ADB279639	
ADB263763	
ADB283958	
ADB262379	
ADB283894	
ADB283063	
ADB261795	
ADB263454	
ADB281633	
ADB283877	
ADB284034	
ADB283924	
ADB284320	
ADB284135	
ADB259954	
ADB258194	
ADB266157	
ADB279641	
ADB244802	
ADB257340	
ADB244688	
ADB283789	
ADB258856	
ADB270749	
ADB258933	